HRP20150946T1 - Postupci uporabe alk-inhibitora - Google Patents

Postupci uporabe alk-inhibitora Download PDF

Info

Publication number
HRP20150946T1
HRP20150946T1 HRP20150946TT HRP20150946T HRP20150946T1 HR P20150946 T1 HRP20150946 T1 HR P20150946T1 HR P20150946T T HRP20150946T T HR P20150946TT HR P20150946 T HRP20150946 T HR P20150946T HR P20150946 T1 HRP20150946 T1 HR P20150946T1
Authority
HR
Croatia
Prior art keywords
compound
phenyl
isopropoxy
chloro
piperidin
Prior art date
Application number
HRP20150946TT
Other languages
English (en)
Croatian (hr)
Inventor
Nanxin LI
Jennifer L. Harris
Peter McNAMARA
Fangxian SUN
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150946(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20150946T1 publication Critical patent/HRP20150946T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20150946TT 2011-02-02 2012-02-02 Postupci uporabe alk-inhibitora HRP20150946T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors
EP12703670.5A EP2670401B1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (1)

Publication Number Publication Date
HRP20150946T1 true HRP20150946T1 (hr) 2015-10-09

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150946TT HRP20150946T1 (hr) 2011-02-02 2012-02-02 Postupci uporabe alk-inhibitora

Country Status (22)

Country Link
US (1) US8703787B2 (cg-RX-API-DMAC7.html)
EP (1) EP2670401B1 (cg-RX-API-DMAC7.html)
JP (1) JP5837095B2 (cg-RX-API-DMAC7.html)
KR (1) KR101521861B1 (cg-RX-API-DMAC7.html)
CN (1) CN103458881B (cg-RX-API-DMAC7.html)
AU (1) AU2012212142B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013019643B1 (cg-RX-API-DMAC7.html)
CA (1) CA2824092C (cg-RX-API-DMAC7.html)
CY (1) CY1116662T1 (cg-RX-API-DMAC7.html)
DK (1) DK2670401T3 (cg-RX-API-DMAC7.html)
EA (1) EA023404B1 (cg-RX-API-DMAC7.html)
ES (1) ES2543567T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150946T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025395T2 (cg-RX-API-DMAC7.html)
ME (1) ME02200B (cg-RX-API-DMAC7.html)
MX (1) MX2013008791A (cg-RX-API-DMAC7.html)
PL (1) PL2670401T3 (cg-RX-API-DMAC7.html)
PT (1) PT2670401E (cg-RX-API-DMAC7.html)
RS (1) RS54189B1 (cg-RX-API-DMAC7.html)
SI (1) SI2670401T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500300B (cg-RX-API-DMAC7.html)
WO (1) WO2012106540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
RU2015121424A (ru) * 2012-11-07 2016-12-27 Новартис Аг Комбинированная терапия
CN104109149B (zh) 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
WO2015003658A1 (en) * 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのalk阻害剤とcdk阻害剤との組合せ
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR20160100975A (ko) * 2013-12-23 2016-08-24 노파르티스 아게 제약 조합물
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
EP3159338A4 (en) * 2014-06-17 2018-01-24 Korea Research Institute of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
EP3287463A4 (en) 2015-04-24 2018-07-11 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技(苏州)有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
WO2018044767A2 (en) * 2016-08-29 2018-03-08 The Regents Of The University Of Michigan Aminopyrimidines as alk inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SI2287156T1 (sl) * 2003-08-15 2013-09-30 Novartis Ag 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
WO2008007368A2 (en) 2006-07-10 2008-01-17 Rf Dynamics Ltd. Food preparation
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP2311807B1 (en) * 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
WO2008073687A2 (en) 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
KR101238585B1 (ko) * 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물

Also Published As

Publication number Publication date
RS54189B1 (sr) 2015-12-31
ES2543567T3 (es) 2015-08-20
US8703787B2 (en) 2014-04-22
PL2670401T3 (pl) 2015-11-30
KR20130121174A (ko) 2013-11-05
CA2824092A1 (en) 2012-08-09
KR101521861B1 (ko) 2015-05-21
EP2670401B1 (en) 2015-06-10
CN103458881A (zh) 2013-12-18
AU2012212142B2 (en) 2015-09-24
PT2670401E (pt) 2015-10-12
US20130296357A1 (en) 2013-11-07
EA023404B1 (ru) 2016-05-31
CY1116662T1 (el) 2017-03-15
MX2013008791A (es) 2013-10-07
ME02200B (me) 2016-02-20
WO2012106540A1 (en) 2012-08-09
CA2824092C (en) 2020-06-30
AU2012212142A1 (en) 2013-08-15
JP2014504646A (ja) 2014-02-24
DK2670401T3 (en) 2015-09-07
SI2670401T1 (sl) 2015-10-30
BR112013019643B1 (pt) 2022-04-19
SMT201500300B (it) 2016-01-08
EA201391114A1 (ru) 2013-12-30
EP2670401A1 (en) 2013-12-11
BR112013019643A2 (pt) 2016-10-04
JP5837095B2 (ja) 2015-12-24
CN103458881B (zh) 2015-08-12
HUE025395T2 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
HRP20150946T1 (hr) Postupci uporabe alk-inhibitora
PE20161246A1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
JP2014504646A5 (cg-RX-API-DMAC7.html)
CY1125613T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
MX2012006562A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-( 4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas.
PH12016501258A1 (en) Cortistatin analogues and syntheses and uses thereof
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
HRP20140953T1 (hr) Morfolino pirimidini i njihova uporaba za lijeäśenje
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
BR112014027117A2 (pt) derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201790228A1 (ru) Композиции и способы получения пиримидиновых и пиридиновых соединений с btk ингибирующей активностью
PH12013500880A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3